id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
bjp-25731	Ajani, Olayinka Oyewale; Aderohunmu, Damilola Victoria; Umeokoro, Ejike Nzube; Olomieja, Ayodele Ojo	Quinazoline pharmacophore in therapeutic medicine	2016	19	.pdf	application/pdf	11703	685	53	Gefitinib and erlotinib are quinazoline-based compounds which happened to be earlier reported salient EGFR inhibitor authorized for the curing of diseases related to NSCLC (Wang et al., 2016). Their mechanism of action was through competi- tive binding to adenosine triphosphate (ATP)-binding pocket of the intracellular EGFR TK site according to docking study report; hence, effectively block the aberrant EGFR down-stream signaling required during tumor survival as well as its proliferation (Wang et al., 2016; Hynes and Lane, 2005).	cache/bjp-25731.pdf	txt/bjp-25731.txt